For research and educational purposes only. Not medical advice.

Eloralintide Reference

Educational, not medical advice reference for Eloralintide: Metabolic, Fat Loss; regulatory status, evidence posture, source review, and schedul…

Plain English

What it is
Eloralintide is an experimental once-a-week shot being developed by Eli Lilly. It copies the action of a natural body hormone called amylin, which helps tell your brain you are full after eating. It is not a GLP-1 drug like semaglutide; it works through a different fullness signal.
What people use it for
It is being tested as a weight-loss treatment for adults with obesity or who are overweight. In studies, people are given it to see if reducing appetite and calorie intake leads to steady weight loss.
What the science shows
In a roughly one-year mid-stage (phase 2) study of a few hundred adults, people on eloralintide lost meaningfully more weight than people on a dummy shot, with the highest groups losing up to about one-fifth of their body weight. The most common side effects were mild stomach symptoms (like nausea) and tiredness, more likely at higher amounts.
The catch
It is still experimental and has not been approved by the FDA or any regulator, so it is not sold legally to consumers. The results come from just one mid-stage trial, and larger, longer studies are still needed to confirm how well it works and how safe it is over time. Anything sold online as eloralintide is unverified and outside safety oversight.

Reference summary

Human evidence rests on one completed 48-week phase 2 randomized, placebo-controlled trial (263 adults with obesity or overweight without type 2 diabetes) plus earlier phase 1 work. Mean weight change at 48 weeks ranged from about 9 percent at the lowest level to about 20 percent at the highest, versus roughly flat placebo (Lilly reported up to about 20 percent). The most common adverse events were mild-to-moderate gastrointestinal symptoms (such as nausea) and fatigue, seen more frequently at higher levels, with lower rates on slower step-up and rates similar to placebo at the lowest levels. Mechanistically it selectively activates the amylin receptor, a different pathway from GLP-1 drugs. These are single-phase-2 findings, not confirmatory or long-term safety data.

Regulatory and posture

Categories
Metabolic, Fat Loss
Aliases
LY3841136, Lilly selective amylin agonist, amylin receptor agonist
Evidence posture
human - Investigational and not FDA-approved: human data are limited to one phase 2 trial (plus phase 1); no long-term or broad-population safety data.
Regulatory status
Investigational. Eloralintide (LY3841136) is an Eli Lilly selective amylin receptor agonist given once weekly by subcutaneous injection. It is NOT FDA-approved and is not approved by any regulator. It completed a 48-week phase 2 obesity trial and Lilly has announced plans to begin phase 3. There is no approved label and no legal consumer supply; any material sold as eloralintide outside a trial is unverified.
Content review status
investigational verified

Selected public sources

Related tools